Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$14.70
+0.1%
$14.64
$6.41
$14.77
$940.21M0.84757,360 shs2.39 million shs
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
C$0.04
-12.5%
C$0.05
C$0.03
C$0.09
C$1.33M0.475,091 shs2,000 shs
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
$44.59
+0.3%
$43.84
$32.15
$45.02
$2.96B0.561.08 million shs1.06 million shs
(FIRE) stock logo
FIRE
(FIRE)
$0.00
$0.00
$0.00
N/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$4.75
C$4.26
C$3.34
C$7.12
C$151.62M1.169,650 shs2,000 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00%0.00%0.00%0.00%0.00%
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
0.00%-12.50%-22.22%-22.22%-36.36%
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
+0.29%+1.55%+4.52%+6.83%+37.92%
(FIRE) stock logo
FIRE
(FIRE)
0.00%0.00%0.00%0.00%0.00%
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
0.00%-2.86%+23.70%+16.42%-20.83%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
N/AN/AN/AN/AN/AN/AN/AN/A
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
N/AN/AN/AN/AN/AN/AN/AN/A
(FIRE) stock logo
FIRE
(FIRE)
N/AN/AN/AN/AN/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
0.0571 of 5 stars
1.10.01.70.00.60.80.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
N/AN/AN/AN/A
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
0.00
N/AN/AN/A
(FIRE) stock logo
FIRE
(FIRE)
N/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
2.25
HoldC$4.58-3.68% Downside

Current Analyst Ratings

Latest BMK, AMYT, HLS, FIRE, and EPI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$6.50 ➝ C$5.00
3/15/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$4.35 ➝ C$4.15
2/22/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$5.00 ➝ C$4.35
2/6/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Clarus Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$222.54M4.22$0.98 per share14.98$5.58 per share2.63
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
C$-74K-17.92C$0.00 per share13.00C($0.01) per share-3.50
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
N/AN/AN/AN/AN/AN/A
(FIRE) stock logo
FIRE
(FIRE)
N/AN/AN/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$63.07M2.40C$0.31 per share15.22C$3.06 per share1.55

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
-C$1.28M-C$0.02N/AN/AN/A-1,679.48%-324.12%6/4/2024 (Estimated)
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
N/AN/A15.51N/AN/AN/AN/AN/A
(FIRE) stock logo
FIRE
(FIRE)
N/AN/A0.00N/AN/AN/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
-C$27.53M-C$1.16N/AN/A-43.65%-24.69%-2.87%5/9/2024 (Estimated)

Latest BMK, AMYT, HLS, FIRE, and EPI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
-C$0.13-C$0.18-C$0.05-C$0.13C$21.83 millionC$21.60 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
N/AN/AN/AN/AN/A
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
$1.964.40%N/AN/AN/A
(FIRE) stock logo
FIRE
(FIRE)
N/AN/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$0.204.21%N/AN/A N/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.64
1.57
0.94
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
3.84
0.22
0.27
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
N/AN/AN/A
(FIRE) stock logo
FIRE
(FIRE)
N/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
89.69
1.65
1.01

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
2,02063.96 million60.34 millionNot Optionable
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
237.88 millionN/ANot Optionable
WisdomTree India Earnings Fund stock logo
EPI
WisdomTree India Earnings Fund
N/A66.40 millionN/ANot Optionable
(FIRE) stock logo
FIRE
(FIRE)
N/AN/AN/ANot Optionable
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
9131.92 millionN/ANot Optionable

BMK, AMYT, HLS, FIRE, and EPI Headlines

SourceHeadline
Branching Regulatory Paths and Dead Ends in PsychedelicsBranching Regulatory Paths and Dead Ends in Psychedelics
theregreview.org - April 15 at 1:53 AM
Who Is Cara Mund? Former Miss America Who Supports Abortion Rights Announces Run for US House as Republican in North DakotaWho Is Cara Mund? Former Miss America Who Supports Abortion Rights Announces Run for US House as Republican in North Dakota
ibtimes.sg - April 10 at 12:16 AM
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 9 at 8:27 AM
Cara Mund running for US House in North Dakota Republican primaryCara Mund running for US House in North Dakota Republican primary
bismarcktribune.com - April 8 at 5:55 PM
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
finance.yahoo.com - April 8 at 7:31 AM
Getting to Yes, And…| Elaine Lin Hering – Unlearning SilenceGetting to Yes, And…| Elaine Lin Hering – Unlearning Silence
wgnradio.com - April 2 at 10:55 AM
Earnings Release: Heres Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57Earnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57
finance.yahoo.com - March 17 at 10:03 AM
HLS has price target cut at Raymond JamesHLS has price target cut at Raymond James
cantechletter.com - March 15 at 8:14 PM
HLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%HLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%
finance.yahoo.com - March 14 at 12:41 PM
HLS Therapeutics Announces Fiscal 2023 Financial ResultsHLS Therapeutics Announces Fiscal 2023 Financial Results
finance.yahoo.com - March 14 at 7:34 AM
HLS Therapeutics earnings: heres what to expectHLS Therapeutics earnings: here's what to expect
markets.businessinsider.com - March 13 at 10:32 AM
Amicus Curiae Returning to CampusAmicus Curiae Returning to Campus
marshallparthenon.com - February 21 at 1:11 PM
Several Insiders Invested In HLS Therapeutics Flagging Positive NewsSeveral Insiders Invested In HLS Therapeutics Flagging Positive News
finance.yahoo.com - February 21 at 1:11 PM
Stocks in play: HLS Therapeutics Inc.Stocks in play: HLS Therapeutics Inc.
ca.finance.yahoo.com - February 6 at 1:07 PM
HLS Announces that Vascepa® is now reimbursed by British Columbias Provincial Drug PlanHLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
finance.yahoo.com - February 6 at 7:35 AM
Jennifer J. Raab named President and CEO of The New York Stem Cell FoundationJennifer J. Raab named President and CEO of The New York Stem Cell Foundation
eurekalert.org - January 31 at 10:48 PM
Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023
msn.com - December 20 at 11:16 AM
HLS Therapeutics CFO Tim Hendrickson to Step DownHLS Therapeutics CFO Tim Hendrickson to Step Down
marketwatch.com - December 18 at 7:58 AM
HLS Therapeutics appoints John Hanna as interim CFOHLS Therapeutics appoints John Hanna as interim CFO
msn.com - December 18 at 7:58 AM
HLS Therapeutics Announces CFO DepartureHLS Therapeutics Announces CFO Departure
finance.yahoo.com - December 18 at 7:58 AM
2 Top Pharmaceutical Stocks to Buy on the TSX Today2 Top Pharmaceutical Stocks to Buy on the TSX Today
msn.com - December 11 at 7:41 PM
Cerebral venous thrombosis should be considered in a postpartum patient with headache and seizureCerebral venous thrombosis should be considered in a postpartum patient with headache and seizure
cmaj.ca - December 11 at 9:41 AM
Some HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Years EstimatesSome HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates
finance.yahoo.com - November 15 at 7:05 AM
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineNew REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
finance.yahoo.com - November 14 at 5:47 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Amryt Pharma logo

Amryt Pharma

NASDAQ:AMYT
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
MacDonald Mines Exploration logo

MacDonald Mines Exploration

CVE:BMK
MacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interest in the Scadding-Powerline-Jovan property that covers an area of 19,710 hectares located to the east of Sudbury in Northern Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was incorporated in 1936 and is based in Toronto, Canada.
WisdomTree India Earnings Fund logo

WisdomTree India Earnings Fund

NYSEARCA:EPI
WisdomTree India Earnings Fund (The Fund) seeks to track the price and yield performance, before fees and expenses, of the WisdomTree India Earnings Index. The Index measures the performance of profitable companies incorporated and traded in India that are eligible to be purchased by foreign investors and that meet specific criteria developed by WisdomTree Investments.
(FIRE) logo

(FIRE)

NASDAQ:FIRE
Sourcefire, Inc. (Sourcefire) is engaged in the business of delivering intelligent cybersecurity technologies. The Company provides a portfolio of solutions that enables commercial enterprises and government agencies worldwide to manage and minimize cybersecurity risks. Sourcefire provides customers with Agile Security that consists of hardware with embedded software, software and cloud-based solutions. It sells its solutions to a customer base that includes Global 2000 companies, global enterprises, the United States and international government agencies, and small and mid-size businesses. During the year ended December 31, 2012, it generated approximately 67% of the Company's revenue from customers in the United States, and 33% of the Company's revenue from customers outside of the United States. As of December 31, 2012, its product revenue and services revenue represented 61% and 39% of its total revenue, respectively.
HLS Therapeutics logo

HLS Therapeutics

TSE:HLS
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.